27th Feb 2008 18:00
AstraZeneca PLC27 February 2008 Transaction by Persons Discharging Managerial ResponsibilitiesDisclosure Rule DTR 3.1.4 We hereby inform you that the interest of David R. Brennan, a Director of theCompany, in the shares of AstraZeneca PLC has changed as detailed below. MrBrennan has interests in both the Ordinary Shares and the American DepositaryShares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary Share. On 25 February 2008, Mr Brennan received an allocation of 16,810 Ordinary Sharesunder the previously disclosed arrangements relating to his annual bonus for2007 whereby he is required to defer a portion of the bonus earned into sharesfor a period of three years. The shares were allocated at a price of 1999 penceper share. Mr Brennan will become beneficially entitled to these shares on 25February 2011. On 25 February 2008, Mr Brennan received a scheduled distribution out of theAstraZeneca US Executive Deferral Plan, a unitised stock fund established in2000, in which Mr Brennan, in common with other participating US executives, isdeemed to have a notional interest in ADSs calculated by reference to the fundvalue and the closing price of AstraZeneca ADSs. Following this scheduleddistribution on 25 February 2008, Mr Brennan had a notional interest in 40,286ADSs within the AstraZeneca US Executive Deferral Plan by reference to theclosing price on 25 February 2008 of US$39.47. Immediately prior to the above transactions, Mr Brennan had an interest in217,618 Ordinary Shares and 143,617 AstraZeneca ADSs. As a result of thesetransactions, Mr Brennan's interest is now 234,428 Ordinary Shares and 121,435AstraZeneca ADSs, including the notional interest in ADSs in the AstraZeneca USExecutive Deferral Plan referred to above. This interest representsapproximately 0.024% of the Company's issued ordinary capital. G H R MuskerCompany Secretary27 February 2008 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca